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CONCLUSIONS: EQ-5D detects significant differences
in health status between patients with known mental
health problems, and is sensitive to changes in patients
with diagnosed mental illness. However, the anxiety/de-
pression dimension may have different sensitivity to its
two components.
TPQL7
THE EFFECT OF ORDER OF ADMINISTRATION 
OF GENERIC AND DISEASE-SPECIFIC QUALITY 
OF LIFE QUESTIONNAIRES
Lee TA, Sullivan SD
University of Washington, Seattle, WA, USA
OBJECTIVES: The purpose of this study was to deter-
mine if order of completion of the Asthma Quality of Life
Questionnaire (AQLQ) and the Short-Form 36 (SF-36)
affected responses to domain or summary scores.
METHODS: A double-blind, randomized cost-effective-
ness trial compared triamcinolone 800 g per day versus
placebo in adult asthmatics over 12 months. Within the
clinical trial, 124 patients were randomized at the base-
line visit to one of two groups in which the order of the
self-administered health status questionnaires was alter-
nated. The first group received the AQLQ followed by
the SF-36 (N  63), and the second group was reversed
(N  61). Scores from the eight domains of the SF-36
and the four domains of the AQLQ were compared be-
tween the two groups. The groups were also compared
with regard to the overall quality of life score from the
AQLQ and the two summary scales from the SF-36.
RESULTS: The two groups did not differ significantly in
any of the domain scores, SF-36 summary scores, or the to-
tal score on the AQLQ. The overall quality of life score
from the AQLQ was 4.566 in the group that received the
AQLQ first and 4.702 in the SF-36 first group (p  0.500).
The summary estimates for the physical component sum-
mary scale (PCS) were 75.0 for the AQLQ first group and
74.1 for the SF-36 first group (p  0.589). The mental
health component summary scale (MCS) estimates were
74.3 versus 73.7 (p  0.711) for the respective groups.
CONCLUSION: The order in which questionnaires were
administered did not affect the domain or component
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About 270,000 surgeries for total or partial hip replace-
ment are performed annually in the United States. Pa-
tients not receiving prophylaxis agents result in an unac-
ceptably high incidence of deep vein thrombosis (DVT)
and pulmonary embolism (PE). The primary agents used
to prevent these complications are warfarin and low mo-
lecular weight heparins.
OBJECTIVES: This study examined the cost and out-
comes of hip surgery patients seen at Graduate Hospital
from October 1994 to September 1995.
METHODS: Economic and clinical outcomes data were
collected respectively for patients undergoing hip surgery
at Graduate Hospital in Philadelphia. The data were ana-
lyzed utilizing a risk adjusted outcome program devel-
oped for the Corporate Hospital Rating Project. Direct
costs were calculated using Medicare cost reporting data
by the hospital’s finance department.
RESULTS: Fifty-three patients were analyzed. Four re-
ceived both enoxaparin and warfarin, one received nei-
ther. These patients were excluded from the analysis. Re-
sults indicate the total direct cost ($6860 versus $10,320),
LOS (6.6d versus 10.5d) and complication rate (39.6%
versus 50.7%) were lower with warfarin versus enox-
aparin. Risk adjusted data also favored warfarin. There
was no evidence of DVT or PE in either group during the
6-month follow-up period after discharge.
CONCLUSIONS: The purported advantages of enox-
aparin over warfarin were not seen in our institution.
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Although postsurgical adhesions following general abdomi-
nal surgery are directly responsible for negative clinical out-
comes that require additional medical management and sur-
gical re-intervention (and concomitant costs), the magnitude
of these outcomes is not readily understood. Previous stud-
ies have been primarily case series in academic centers.
OBJECTIVE: We sought to establish the incidence of small-
bowel obstruction, adhesiolysis for obstruction, and addi-
tional abdominal surgery following open colorectal and
general surgery among the elderly across all settings.
METHODS: We conducted a retrospective cohort study
using patient-specific HCFA data to evaluate a random
5% sample of all Medicare patients undergoing surgery
in 1993. Of these, 18,912 patients had an index abdomi-
nal procedure. Two-year follow-up data documented
outcomes of hospitalizations with obstruction, adhesioly-
sis for obstruction, and/or additional open colorectal or
general surgery.
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RESULTS: Within 2 years of incision, excision and anas-
tomosis of intestine, 14.3% of patients had obstruction,
2.6% required an adhesiolysis for obstruction, and
12.9% underwent additional open colorectal or general
surgery. After other operations of intestine, 17% of pa-
tients had obstruction, 3.1% required an adhesiolysis,
and 20.2% underwent additional surgery. After opera-
tions of rectum, rectosigmoid and perirectal tissue, 15.3%
of patients had obstruction, 5.1% required an adhesioly-
sis, and 16.4% underwent additional surgery.
CONCLUSIONS: In this study of Medicare patients,
bowel obstruction, adhesiolysis for obstruction, and ad-
ditional abdominal surgery occurred more often after ab-
dominal surgery than previously published.
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OBJECTIVE: To compare the effectiveness and costs of
care for nifedipine-CC and amlodipine when used for ini-
tial management of uncomplicated hypertension.
METHODS: A retrospective analysis was conducted us-
ing outpatient pharmacy, provider, and hospital dis-
charge claims records of continuously eligible Pennsylva-
nia Medicaid patients started on either drug in 1994
without prescriptions for other anti-hypertensive agents
or reported cardiovascular complications in the 8 months
prior to initial nifedipine-CC or amlodipine prescription.
Comparison of three indicators of change in prescrip-
tions were evaluated to provide information on medica-
tion effectiveness. Chi-square tests of association were
conducted to evaluate effectiveness indicators while lin-
ear regression was utilized to compare costs.
RESULTS: Patients satisfying inclusion/exclusion crite-
ria who received nifedipine-CC (n  151) or amlodipine
(n  316) had similar demographic characteristics and
levels of comorbidity. A slightly greater percentage of pa-
tients started on nifedipine-CC had prescription records
consistent with cross-over to a different calcium channel
blocker (15.3% versus 10.3%) while a greater percentage
of patients started on amlodipine had records consistent
with cross-over to another class of anti-hypertensive
agent (7.3% versus 13.2%). In adherent patients, other
anti-hypertensive drugs were added to each regimen to a
similar extent and no differences were found in adverse
events that were reported. Total pharmacy costs were de-
termined to be significantly higher (p  0.0001) in pa-
tients started on amlodipine ($2536 higher in patients
with the most comorbidity to $293 in the least).
CONCLUSIONS: The results suggest these drugs have
similar effectiveness and that physicians’ drug preferences
can have important effects on total pharmacy costs.
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OBJECTIVE: The purpose of this study is to evaluate the
cost-effectiveness of the immunosuppressive regimen, cy-
closporine, mycophenolate mofetil, and prednisone (CMP),
in improving 3-year graft survival in kidney transplant re-
cipients as compared to the immunosuppressive regimen,
cyclosporine, azathioprine, and prednisone (CAP).
METHODS: A sample of kidney transplant recipients re-
ceiving either cadaveric or living donor transplants in
1996 was selected from the United States Renal Data Sys-
tem (USRDS). Direct costs were estimated from Medicare
reimbursements and included: outpatient costs, hospital-
ization costs due to rejection episodes, infectious compli-
cations, or graft failure, dialysis costs due to graft failure,
and medication costs. The effectiveness measure was
length of graft survival and expressed as the total number
of life-months with an intact graft. A Markov model in-
cluding three Markov states (e.g., graft intact, return to
dialysis as a result of graft failure, and death) and two
transient states (e.g., graft rejection and complications)
was used to model the course of progression and continu-
ous risk of graft rejection. The USRDS data were also
used to estimate transplant recipients’ transition proba-
bilities throughout the Markov stages.
RESULTS: Although mycophenolate mofetil costs sub-
stantially more than azathioprine ($6000 versus $1000
annually), preliminary findings suggest that the CMP reg-
imen is more cost-effective than CAP because of the re-
duction in hospitalizations and treatment costs saved by
avoiding acute graft rejection episodes.
CONCLUSIONS: Our study provides valuable informa-
tion regarding the most cost-effective immunosuppressive
regimen to renal transplant centers. Findings from this
study will also be of interest to the Medicare End-Stage
Renal Disease (ERSD) program since a majority of the kid-
ney transplant patients were covered under this program.
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